NCT01520558View on ClinicalTrials.gov

CNDO-109-AANK for AML in First Complete Remission (CR1)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

February 28, 2018

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CNDO-109-AANK Cells

Single dose, infusion

Trial Locations (4)

29425

Medical University of South Carolina, Charleston

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

55455

University of Minnesota - Masonic Cancer Center, Minneapolis

63110

Washington University, St Louis

Sponsors
All Listed Sponsors
lead

Coronado Biosciences, Inc.

INDUSTRY